Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.
FAIL · Does not pass the screen
16.33 USD
Price as of 6 Nov 2026Daily close, not a live quote
Screened 2026-11-06 · the tape above runs as of 20:08 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price16.33 USD at the 6 Nov 2026 close
Fair valueUnder review: our model's value is 2.03x the price, above our 2.00x limit.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 1.42, read 2026-11-02
Ethical does not pass the values gate
Price16.33 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-10-15Read Markdown17.59-7.2% to today ✓Accumulation gives way to Markdown first Markdown read since August
2026-10-11Read Accumulation17.17-4.9% to today Markup gives way to Accumulation after an 18% rise in 4 weeks
2026-09-13Read Markup14.60+11.8% to today ✓Markdown gives way to Markup after a 9% rise in 4 weeks
2026-08-13Read Markdown13.44+21.5% to today Distribution gives way to Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Summit Therapeutics Inc holds its Markdown at $16.33. The statistical read favours the sellers, held for 80 days.
As held on the ledger · 2026-11-06
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 80 days
Price at the screen
$16.33
Valuation
N/A trailing · -13.90 forward price to earnings
Values screen
FAIL· score 70.0
Beta
-1.52
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
2.78%
Below 33%
Interest-bearing debt is just 2.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
64.99%
Below 33%
Interest-bearing cash and securities are 65.0% of assets, above the one-third limit.
Fail
Receivables
29.99%
Below 49%
Money owed to the company is 30.0% of assets, under the 49% limit.
Pass
Revenue purity
214.61%
Below 5%
214.6% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Summit Therapeutics's business is fine, but its cash and interest-bearing securities are about 65% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when SMMT's ethical verdict changes
Today SMMT does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Fair value under review. Our model's value is 2.03x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Biotech dreams rarely survive first contact
Picture a drug still in trials that needs to clear regulators, win doctors and then scale across hospitals before any cash lands. Summit is that story today, with ivonescimab its single bet and no profits yet to show for the effort. The numbers underline the gap: forward earnings sit at minus 11.7 times, margins at zero and return on equity at minus 271 percent.
Analysts see upside and the ethical screen clears, yet the opportunity rating stays at none. A narrow moat plus heavy cash burn means any delay or rival advance could wipe out the apparent discount to fair value. The market has already priced in hope; execution risk sits elsewhere.
Even a clean trial result leaves years of spending and competition before real returns appear. Peak losses can persist long after the share price has run. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
SMMT trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-03Markdown$16.03+0.0%Entry 29
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (13 analysts) rates it buy, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markdown$16.03+0.0%Entry 28
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (13 analysts) rates it buy, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markdown$16.03+10.6%Entry 27
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 10.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (13 analysts) rates it buy, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Markdown$14.50+0.0%Entry 26
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (13 analysts) rates it buy, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Markdown$14.50+0.0%Entry 25
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (13 analysts) rates it buy, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Markdown$14.50+0.0%Entry 24
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (13 analysts) rates it buy, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markdown$14.50-4.2%Entry 23
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (13 analysts) rates it buy, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markdown$15.13+0.0%Entry 22
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (13 analysts) rates it buy, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markdown$15.13+0.0%Entry 21
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (13 analysts) rates it buy, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Markdown$15.13+0.0%Entry 20
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (13 analysts) rates it buy, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
